Sol-Gel将向PellePharm支付470万美元的预付款,以及高达600万美元的开发和NDA验收里程碑,以及高达6400万美元的商业里程碑和分成。
Patidegib被Sol-Gel指定为SGT-610,用于治疗Go...查看全文
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-19-002969 Act: 34 Size: 3 MB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-19-002760 Act: 34 Size: 269 KB 网页链接
$Sol-gel(SLGL)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-09-18 AccNo: 0001178913-19-002355 Size: 146 KB 网页链接
$Sol-gel(SLGL)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2019-08-21 AccNo: 0001178913-19-002229 Size: 53 KB 网页链接
$Sol-gel(SLGL)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-08-13 AccNo: 0001178913-19-002152 Size: 2 MB 网页链接
$Sol-gel(SLGL)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-08-08 AccNo: 0001178913-19-002093 Size: 15 KB 网页链接
$Sol-gel(SLGL)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2019-08-08 AccNo: 0001178913-19-002102 Size: 731 KB 网页链接
$Sol-gel(SLGL)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-08-08 AccNo: 0001178913-19-002139 Size: 437 KB 网页链接
$Sol-gel(SLGL)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-07-25 AccNo: 0001178913-19-001946 Size: 6 MB 网页链接
$Sol-gel(SLGL)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-07-23 AccNo: 0001178913-19-001938 Size: 4 MB 网页链接